Down-regulation of estrogen receptor by the methylation of the estrogen receptor gene in endometrial carcinoma. 2002

Tanri Shiozawa, and Kazuko Itoh, and Akiko Horiuchi, and Ikuo Konishi, and Shingo Fujii, and Toshio Nikaido
Department of Obstetrics and Gynecology, Shinshu University School of Medicine, Matsumoto, Japan. tanri@hsp.md.shinshu-u.ac.jp

BACKGROUND Human uterine endometrial carcinomas are composed of estrogen receptor (ER)-positve and ER-negative subgroups, though the mechanisms that down-regulate the ER expression are not understood. The present study was undertaken to examine the involvement of methylation of the ER gene on the ER status. METHODS DNA was extracted from 25 cases of endometrial carcinoma. Polymerase chain reaction (PCR), using the extracted DNA and methylation-sensitive restriction enzymes (Hpa II, Hha I), was performed to detect the methylation of a CpG island in the ER (alpha) gene. The results were compared with the ER expression by immunostaining. RESULTS In the 25 endometrial carcinomas, methylation at the Hpa II site, or at both the Hpa II and Hha I sites, was found in 6 cases, while methylation was not found in the remaining 19 cases. Immunohistochemically, 5 of the 6 methylation-positive cases were negative for ER, whereas 14 of the 19 methylation-negative cases were ER-positive (p=0.02). CONCLUSIONS Methylation of the CpG island of the ER gene is inversely correlated with ER expression in a subset of endometrial carcinomas.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor

Related Publications

Tanri Shiozawa, and Kazuko Itoh, and Akiko Horiuchi, and Ikuo Konishi, and Shingo Fujii, and Toshio Nikaido
June 2007, Cancer genetics and cytogenetics,
Tanri Shiozawa, and Kazuko Itoh, and Akiko Horiuchi, and Ikuo Konishi, and Shingo Fujii, and Toshio Nikaido
July 1995, Obstetrics and gynecology,
Tanri Shiozawa, and Kazuko Itoh, and Akiko Horiuchi, and Ikuo Konishi, and Shingo Fujii, and Toshio Nikaido
January 1989, Journal of steroid biochemistry,
Tanri Shiozawa, and Kazuko Itoh, and Akiko Horiuchi, and Ikuo Konishi, and Shingo Fujii, and Toshio Nikaido
June 2009, Endocrine-related cancer,
Tanri Shiozawa, and Kazuko Itoh, and Akiko Horiuchi, and Ikuo Konishi, and Shingo Fujii, and Toshio Nikaido
January 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
Tanri Shiozawa, and Kazuko Itoh, and Akiko Horiuchi, and Ikuo Konishi, and Shingo Fujii, and Toshio Nikaido
February 2018, Anticancer research,
Tanri Shiozawa, and Kazuko Itoh, and Akiko Horiuchi, and Ikuo Konishi, and Shingo Fujii, and Toshio Nikaido
June 2005, Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences,
Tanri Shiozawa, and Kazuko Itoh, and Akiko Horiuchi, and Ikuo Konishi, and Shingo Fujii, and Toshio Nikaido
December 2005, Journal of toxicology and environmental health. Part A,
Tanri Shiozawa, and Kazuko Itoh, and Akiko Horiuchi, and Ikuo Konishi, and Shingo Fujii, and Toshio Nikaido
February 1998, Molecular and cellular endocrinology,
Tanri Shiozawa, and Kazuko Itoh, and Akiko Horiuchi, and Ikuo Konishi, and Shingo Fujii, and Toshio Nikaido
December 2008, Current opinion in pharmacology,
Copied contents to your clipboard!